Stuart Silverman, MD

Articles by Stuart Silverman, MD

Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MD

October 31st 2022

As the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]

Differences Between Fenebrutinib and Other BTK Inhibitors: Stuart Silverman, MD

ByStuart Silverman, MD

October 21st 2022

The neurologist at Allegheny Health Network’s Neuroscience Institute provided insight on the mechanism of action of fenebrutinib and how it differs from other BTK inhibitors currently in development. [WATCH TIME: 3 minutes]

Stuart Silverman, MD

Articles by Stuart Silverman, MD

Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MD

Differences Between Fenebrutinib and Other BTK Inhibitors: Stuart Silverman, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole

Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows

FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies

New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment

Understanding the Global Impact of the Honolulu Asian Aging Study: George W. Ross, MD